CA-CLICKHOUSE
25.6.2024 17:46:36 CEST | Business Wire | Press release
ClickHouse Inc, a leader in real-time analytics, announces the expansion of ClickHouse Cloud to Microsoft Azure, providing users with even more options for deploying and managing their analytics workloads. With this expansion, ClickHouse Cloud is now available on three major cloud service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625765046/en/
ClickHouse Cloud is now generally available on Microsoft Azure (Graphic: Business Wire)
As organizations increasingly adopt real-time analytics databases in their interactive, data-driven customer-facing applications, as well as in their internal data warehousing and data science workflows, ClickHouse Cloud availability on Azure offers customers greater flexibility and choice. Availability of ClickHouse Cloud in Azure Marketplace allows users to use existing Azure investments and take advantage of integrations with Azure-specific services including Microsoft Power BI and Azure Event Hubs.
“Companies of all sizes trust ClickHouse to gain valuable insights from their data, across a wide variety of use cases,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “This announcement reiterates our vision to bring the best real-time data warehouse to our users regardless of which cloud provider they use.”
“With ClickHouse Cloud generally available on Microsoft Azure, enterprise and digital-native companies alike can take advantage of its breadth of use cases on one of the most open and flexible cloud platforms,” said Erin Chapple, corporate vice president, Azure Core Products and Design at Microsoft. “Mutual customers and partners can now benefit from real-time analytics and business intelligence solutions to gain valuable insights from their data in new ways.”
Public Beta for ClickHouse Cloud on Azure was announced at Microsoft Build in May 2024 and is seeing strong adoption across organizations looking to build real-time analytical applications on top of Azure.
"We are thrilled about the launch of ClickHouse Cloud on Microsoft Azure," said Julian LaNeve, Chief Technology Officer at Astronomer. "Our data platform handles massive volumes of real-time events, and ClickHouse has been instrumental in delivering lightning-fast analytics. With ClickHouse Cloud on Azure, we can deploy and scale effortlessly on Azure's reliable, secure, and scalable infrastructure."
“At BaxEnergy, our mission is to make renewable energy easier, more efficient, affordable, and secure," said Marco Cecconi, Head of R&D of BaxEnergy. “ClickHouse Cloud on Microsoft Azure supports us in conducting advanced analysis on large volumes of data from various renewable energy sources. By generating actionable insights, creating detailed reports, and developing custom dashboards, we empower our customers to achieve better performance and scale their operations effectively. We have been pleasantly surprised by the remarkable speed and flexibility of ClickHouse, and their team has provided us with exceptional dedicated support.”
Some additional benefits of using ClickHouse Cloud on Azure include:
Simplicity. With ClickHouse Cloud, you create your service with a single click. You don't have to worry about the operational complexity of server configurations and cluster topology, shards and replicas, managing backups and restores, durability and fault tolerance, monitoring, or alerts. It just works.
Speed and Scale. ClickHouse Cloud is designed to handle real-time analytics on top of petabyte-scale datasets. There is no need for manual sharding or data movement, as it scales automatically. Our multi-layer cache and other cloud-native performance optimizations ensure impressive query performance for a wide variety of workloads.
Security and Reliability. ClickHouse Cloud has security best practices built in by default. It is configured with network isolation and traffic encryption. ClickHouse builds are additionally hardened, tested, and validated for ClickHouse Cloud. The service is automatically replicated across multiple availability zones for high availability.
Efficiency. ClickHouse Cloud adapts itself to the changing nature of your workloads, scaling up and down as needed. ClickHouse Cloud also takes advantage of shared object storage as its primary storage, while separating compute resources. This dramatically increases flexibility and resource efficiency, delivering industry's best price/performance ratio.
Ecosystem. Easy-to-use integrations allow users to seamlessly ingest data and interface with internal and external systems. A curated set of core and partner integrations vetted to work seamlessly with ClickHouse Cloud are provided in addition to hundreds of community-built integrations. Within the Azure ecosystem, ClickHouse Cloud features turnkey integrations with Azure Event Hubs, Power BI, and Azure Blob Storage.
ClickHouse Cloud offers a 30-day trial that includes $300 free usage credits. To get started, sign up here or subscribe from Azure Marketplace.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625765046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom